Following an overview of maternal and neonatal child health in Nepal and in the districts covered by the project, the briefing outlines the background to the Strengthening Approaches for Maximizing Maternal, Neonatal and Reproductive Health (SAMMAN) project. It then describes the key aspects of the ...two main project approaches: one focused on the community level, and the other on health systems
more
Lancet Glob Health 2015; 385: e387–95. Open Access
Examination of the business behaviour of Boehringer Ingelheim, Bayer and Baxter in Uganda
Conhecimento, atitudes e práticas sobre tuberculose em prisões e no serviço público de saúde
Rev Bras Epidemiol 2013; 16(1): 100-113
Dissertation submitted in part fulfilment of the requirements for a Masters degree at the Centre for International Health and Development (CIHD) at University College London (UCL) Institute of Child Health (ICH)
The user has given permission for the uploaded document to be reproduced and made publi...cly available on the source website
more
Early-warning indicators to prevent stock-outs and overstocking of antiretroviral, antituberculosis and antimalaria medicines.
Основная цель этого Руководства состоит в том, чтобы очертить рамки методов, используемых для оценки распространенности ВИЧ-инфекции среди больных туберкулезом и... способствовать осуществле-нию эпиднадзора за ВИЧ-инфекцией.
more
Marco Schäferhoff and colleagues critique funding estimates for the maternal and child health Millennium Development Goals, and make recommendations for improving the tracking of financing flows and estimating the costs of scaling up interventions for mothers and children.
Overcoming barriers in low- and middle-income countries
For the first time, this year’s report includes information on hepatitis C diagnostics. With a focus on selected countries with diverse HCV epidemics, the report provides updates on the various dimensions of access to HCV diagnostics and pha...rmaceutical products, including product pricing, the regulatory environment and patent status, which together shape the national hepatitis response in different settings. It highlights key areas for action by ministries of health and other government decision-makers, pharmaceutical manufacturers and technical partners.
more
Copenhagen, Denmark, 7–8 March 2017. Meeting report
Working Document, September 2017